| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-018 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2002-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07874baf7f20f3983b068cdeb2cd27ed |
| publicationDate |
2005-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005043214-A1 |
| titleOfInvention |
Antiglaucomatous agent and use thereof |
| abstract |
The present invention relates to pharmaceutical compositions based on antiglaucomatous active ingredients and to the use thereof for the treatment of glaucomas. The compositions comprise lactalbumin hydrolysate or a fraction thereof. Substantially lower doses of the antiglaucomatous agents are thus possible than is conventionally necessary to achieve a particular antiglaucomatous effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11395825-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11071724-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015320744-A1 |
| priorityDate |
2001-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |